Granite Investment Partners, LLC Halozyme Therapeutics, Inc. Transaction History

Granite Investment Partners, LLC

$2.54 Billion
Q1 2024

A detailed history of Granite Investment Partners, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Granite Investment Partners, LLC holds 811,458 shares of HALO stock, worth $42.9 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares

811,458

Previous 832,422 2.52%

Holding current value

$42.9 Million

Previous $30.8 Million 7.29%

% of portfolio

1.3%

Previous 1.24%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$33.68 - $41.95 $706,067 - $879,439	-20,964 Reduced 2.52%	811,458 $33 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $794,048 - $1 Million	-23,831 Reduced 2.78%	832,422 $30.8 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $3.58 Million - $4.32 Million	98,135 Added 12.94%	856,253 $32.7 Million
Q2 2023 Aug 07, 2023	BUY	$30.28 - $38.74 $1.3 Million - $1.66 Million	42,871 Added 5.99%	758,118 $27.3 Million
Q1 2023 May 03, 2023	SELL	$32.86 - $55.7 $6.17 Million - $10.5 Million	-187,635 Reduced 20.78%	715,247 $27.3 Million

Q4 2022 Feb 10, 2023	SELL	$40.06 - $59.44 $700,969 - $1.04 Million	-17,498 Reduced 1.9%	902,882 $51.4 Million
Q3 2022 Oct 24, 2022	SELL	$38.53 - $51.78 $529,016 - $710,939	-13,730 Reduced 1.47%	920,380 $36.4 Million
Q2 2022 Jul 22, 2022	BUY	$37.35 - $48.3 $396,022 - $512,124	10,603 Added 1.15%	934,110 $41.1 Million
Q1 2022 May 02, 2022	SELL	$31.97 - $41.06 $353,428 - $453,918	-11,055 Reduced 1.18%	923,507 $36.8 Million
Q4 2021 Feb 10, 2022	BUY	$31.82 - $40.75 $1.41 Million - $1.8 Million	44,166 Added 4.96%	934,562 $37.6 Million
Q3 2021 Nov 03, 2021	SELL	$38.47 - $46.42 $1.1 Million - $1.33 Million	-28,633 Reduced 3.12%	890,396 $36.2 Million
Q2 2021 Jul 30, 2021	BUY	$38.84 - $51.31 $115,160 - $152,134	2,965 Added 0.32%	919,029 $41.7 Million
Q1 2021 May 13, 2021	SELL	$39.51 - $51.45 $1.09 Million - $1.42 Million	-27,618 Reduced 2.93%	916,064 $38.2 Million
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $9.99 Million - $16.9 Million	-387,165 Reduced 29.09%	943,682 $40.3 Million
Q3 2020 Nov 06, 2020	BUY	$25.74 - $29.63 $1.86 Million - $2.14 Million	72,166 Added 5.73%	1,330,847 $35 Million
Q2 2020 Aug 03, 2020	SELL	$16.25 - $26.81 $304,801 - $502,875	-18,757 Reduced 1.47%	1,258,681 $33.7 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $580,158 - $911,140	-41,738 Reduced 3.16%	1,277,438 $23 Million
Q4 2019 Feb 10, 2020	BUY	$14.93 - $19.53 $6.75 Million - $8.82 Million	451,780 Added 52.08%	1,319,176 $23.4 Million
Q3 2019 Nov 12, 2019	BUY	$15.2 - $17.69 $164,661 - $191,635	10,833 Added 1.26%	867,396 $13.5 Million
Q2 2019 Aug 07, 2019	SELL	$14.75 - $17.26 $2.42 Million - $2.83 Million	-164,132 Reduced 16.08%	856,563 $14.7 Million
Q1 2019 May 13, 2019	BUY	$13.94 - $17.58 $442,678 - $558,270	31,756 Added 3.21%	1,020,695 $16.4 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $2.98 Million - $4.18 Million	223,836 Added 29.26%	988,939 $14.5 Million
Q3 2018 Nov 08, 2018	BUY	$16.68 - $18.41 $509,991 - $562,885	30,575 Added 4.16%	765,103 $13.9 Million
Q2 2018 Aug 06, 2018	BUY	$16.87 - $20.3 $48,788 - $58,707	2,892 Added 0.4%	734,528 $12.4 Million
Q1 2018 May 04, 2018	SELL	$17.06 - $21.2 $292,971 - $364,067	-17,173 Reduced 2.29%	731,636 $14.3 Million
Q4 2017 Feb 01, 2018	SELL	$16.75 - $20.8 $1.17 Million - $1.45 Million	-69,696 Reduced 8.52%	748,809 $15.2 Million
Q3 2017 Nov 08, 2017	BUY	$11.76 - $17.4 $9.63 Million - $14.2 Million	818,505	818,505 $14.2 Million

Others Institutions Holding HALO

# of Institutions

442

Shares Held

122M

Call Options Held

216K

Put Options Held

140K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.37B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Investment Partners, LLC with notifications on news.

Account

Granite Investment Partners, LLC Halozyme Therapeutics, Inc. Transaction History